title: Pharmacological manipulation of Ins(1,4,5)P3 signaling mimics preconditioning in rabbit heart.
abstract: Recent evidence revealed biphasic alterations in myocardial concentrations of the second messenger inositol (1,4,5)-trisphosphate [Ins(1,4,5)P3] with ischemic preconditioning (PC), i.e., increase during brief PC ischemia and decrease early during sustained test occlusion. Our aim was to determine whether an agonist and an antagonist of Ins(1,4,5)P(3) signaling (D-myo-inositol-1,4,5-trisphosphate hexasodium salt [D-myo-Ins(1,4, 5)P3] and 2-aminoethoxydiphenyl borate (2-APB), respectively), given such that they mimic this biphasic profile, would mimic infarct size reduction with PC. To test this concept, isolated, buffer-perfused rabbit hearts received no intervention (control), ischemic PC, D-myo-Ins(1,4,5)P3, D-myo-Ins(1,4,5)P(3) + PC, 2-APB, or 2-APB + PC. All hearts then underwent 30-min coronary occlusion and 2 h reflow, and infarct size was delineated by tetrazolium staining. In addition, the effects of D-myo-Ins(1,4,5)P3 and 2-APB on Ins(1,4,5)P3 signaling were evaluated in isolated fura 2-loaded rat cardiomyocytes. Mean infarct size was reduced with PC and in all D-myo-Ins(1,4,5)P3- and 2-APB-treated groups versus control (59 and 42-55%, respectively, vs. 80% of myocardium at risk, P < 0.05). Thus pharmacological manipulation of Ins(1,4,5)P3 signaling mimics the cardioprotection achieved with ischemic PC in rabbit heart.
authors.affiliation: Heart Institute, Good Samaritan Hospital and University of Southern California, Los Angeles, California 90017-2395, USA.
authors.forename: A
authors.initials: A
authors.lastname: Gysembergh
authors.forename: S
authors.initials: S
authors.lastname: Lemaire
authors.forename: C
authors.initials: C
authors.lastname: Piot
authors.forename: C
authors.initials: C
authors.lastname: Sportouch
authors.forename: S
authors.initials: S
authors.lastname: Richard
authors.forename: R A
authors.initials: RA
authors.lastname: Kloner
authors.forename: K
authors.initials: K
authors.lastname: Przyklenk
mesh_terms: D000818:Animals; D001896:Boron Compounds / Q000494:pharmacology; D002316:Cardiotonic Agents; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology*; D006321:Heart / Q000502:physiology / Q000503:physiopathology; D066298:In Vitro Techniques; D015544:Inositol 1,4,5-Trisphosphate / Q000494:pharmacology* / Q000502:physiology; D019194:Ischemic Preconditioning; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D017202:Myocardial Ischemia / Q000503:physiopathology*; D009206:Myocardium / Q000378:metabolism*; D011817:Rabbits; D051381:Rats; D015290:Second Messenger Systems; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D001896:Boron Compounds; D002316:Cardiotonic Agents; D015544:Inositol 1,4,5-Trisphosphate; C109986:2-aminoethoxydiphenyl borate